Gables Capital Management Inc. grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 24.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 79,900 shares of the biopharmaceutical company’s stock after buying an additional 15,500 shares during the period. Gables Capital Management Inc. owned approximately 0.13% of Dynavax Technologies worth $991,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the business. Chicago Capital LLC lifted its position in Dynavax Technologies by 74.0% in the 3rd quarter. Chicago Capital LLC now owns 2,252,046 shares of the biopharmaceutical company’s stock worth $27,925,000 after buying an additional 957,942 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in Dynavax Technologies in the 3rd quarter worth approximately $554,000. Wells Fargo & Company MN lifted its position in Dynavax Technologies by 6.0% in the 3rd quarter. Wells Fargo & Company MN now owns 87,721 shares of the biopharmaceutical company’s stock worth $1,087,000 after buying an additional 4,979 shares during the last quarter. Hikari Power Ltd lifted its position in Dynavax Technologies by 19.1% in the 3rd quarter. Hikari Power Ltd now owns 155,755 shares of the biopharmaceutical company’s stock worth $1,931,000 after buying an additional 25,000 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Dynavax Technologies by 39.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 29,170 shares of the biopharmaceutical company’s stock worth $362,000 after buying an additional 8,220 shares during the last quarter. Hedge funds and other institutional investors own 81.48% of the company’s stock.
Shares of DVAX stock opened at $11.65 on Wednesday. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. Dynavax Technologies Co. has a fifty-two week low of $9.63 and a fifty-two week high of $23.30. The company has a market capitalization of $713.82 million, a price-to-earnings ratio of -6.73 and a beta of 0.61.
A number of analysts recently weighed in on DVAX shares. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Cantor Fitzgerald set a $30.00 price objective on Dynavax Technologies and gave the company a “buy” rating in a research report on Friday, October 19th. BidaskClub upgraded Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 11th. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, Cowen reiterated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research report on Monday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Dynavax Technologies has a consensus rating of “Hold” and an average price target of $28.00.
COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Co. (DVAX) Shares Bought by Gables Capital Management Inc.” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2018/11/07/dynavax-technologies-co-dvax-shares-bought-by-gables-capital-management-inc.html.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Further Reading: What is the float in trading stocks?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.